Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities focusses on the fundamental aspects of Patenting Nanomedicines applied in different Drug Delivery and Targeting Systems . The promoters of new findings in this field of research are numerous and spread worldwide; therefore, managing intellectual property portfolios, and the acquisition and exploitation of new knowledge face several contingency factors. Today, the scientific community is discussing issues of economic outcomes in the field of Nanomedicines. Major concerns include questions as to whether the research groups, academics, industry and other stakeholders should work in unison or independently, if innovation or adaptation of new technology should be prioritized, public versus private research funding, and safeguarding versus sharing knowledge. However, despite its increasing importance for humankind, it is a matter of concern as to whether technological development can really be stimulated by patent protection. An intellectual property strategy should aim to develop a qualitative patent portfolio for continuous learning.

This book addresses questions of ethics, socio-political policies and regulatory aspects of novel Nanomedicine-based products which are currently under development for the diagnosis and treatment of different types of diseases. It is divided in two parts Part I is composed of the first 3 chapters, which focus on the fundamentals of legal aspects, emerging threats, advantages and disadvantages of patenting Nanomedicines, whereas Part II collects 12 chapters discussing different types of Nanomedicine-based products, their potential marketing aspects and patent protection. Whenever applied, each chapter offers a list of patents, based on a specific application in drug delivery and targeting. An outstanding team of 53 authors have contributed to this book, which will be of interest to professionals from the field of patent examiners, academics, researchers and scientists, students and other practitioners.

Emerging Nanotechnologies in Immunology aims to deliver a systematic and comprehensive review of data concerning the nature of interaction and nano-related risks between the nanophamaceuticals currently in the pipeline of S&T development for skin, ocular, and nasal drug delivery, including absorption, toxicity, and the ability to distribute after systemic exposure. The scientific development of manufactured nanomaterials for drug delivery is increasing rapidly. One of the most prominent applications is topical drug delivery, where cutaneous, ocular, and nasal exposure becomes even more relevant. These targets are the first barrier that nanoparticles encounter when in contact with the human body. The contributors addresses a representative set of the broad spectrum of nanopharmaceuticals currently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue engineered skin substitutes. Regulation and risk is also covered, since the safety of these nanophamaceuticals still represents a barrier to their wide innovative use.

"Cell niches" are present in several human body tissues as a dynamic microenvironment essential to modulate stem cells' behavior in health, under injury, and in regenerative processes. The interplay between stem cells and their niche is necessary for sustaining tissues. The extracellular matrix (ECM) is the crucial component of the stem cell. It defines the architectural space, physical binding to the cell membrane, and interactions with the neighborhood cells and supports physical stress. Domains with nano or micrometric sizes define the surface and topology of the ECM, mediating cell interactions and macrophage recruitment to injured sites. Over the last two decades, the integration of biomedicine with other engineering and biomaterial sciences promoted the development of nanotechnology and regenerative medicine toward mimicking the specialized stem cell niches to treat diseases with less invasive and efficient therapies. Innovative approaches in nanotechnology, such as targeting the immunological system, transporting drugs across blood-brain/BBB and blood-retinal barriers/BRB, directing active moiety to specific disease location/organs, encapsulation of multiple components, and promoting signalization and pathway-specific surfaces for cell interactions and growth, are indeed promising. On the other side, developments of biomaterial scaffolds to mimic the cell niches for interactions with stem cells in vitro or in vivo have tremendous potential. The three-dimensional printing technology offers a base for a wide array of applications, for example, developing tissue constructs, mimetic organs, organoids, and organ-on-a-chip, thus avoiding the differences between animal model species and humans. Aiming closer to the natural environments, fresh autologous products from the blood, such as platelet-rich plasma (PRP), contain platelets and leukocytes, providing growth factors, cytokines, and proteins for the resident stem cells in the stages of regeneration. PRP also provides pain relief, reducing disabilities in elderly or diseased people. This book brings thought-provoking multidisciplinary topics on the diverse aspects of basic and applied sciences. The prime focus of the compilation is to understand the challenges researchers encounter in combining nanotechnology and regenerative medicine, ultimately integrating both disciplines for the benefit of the patient and offering them a ray of hope to be cured.

Nanoformulation Strategies for Cancer Treatment provides an up-to-date review on current developments and regulatory and clinical challenges in the field of nanopharmaceuticals and the effective treatment of diverse varieties of cancer. This important reference source is ideal for biomaterials scientists and pharmaceutical scientists working in the area of cancer diagnosis and therapy. Due to the high cost of traditional cancer treatment types, researchers have increasingly looked for new ways to augment the therapeutic performance of existing drug candidates. The use of nanotechnology-based approaches have gained significant momentum, thus leading to the launch of a series of new drug products. As nanopharmaceuticals improve the therapeutic performance of cancer therapy drugs, but also provide opportunities for site-specific drug targeting in tumors, this work is a welcomed resource on the topics discussed.

"Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities" focusses on the fundamental aspects of Patenting Nanomedicines applied in different "Drug Delivery and Targeting Systems". The promoters of new findings in this field of research are numerous and spread worldwide; therefore, managing intellectual property portfolios, and the acquisition and exploitation of new knowledge face several contingency factors. Today, the scientific community is discussing issues of economic outcomes in the field of Nanomedicines. Major concerns include questions as to whether the research groups, academics, industry and other stakeholders should work in unison or independently, if innovation or adaptation of new technology should be prioritized, public versus private research funding, and safeguarding versus sharing knowledge. However, despite its increasing importance for humankind, it is a matter of concern as to whether technological development can really be stimulated by patent protection. An intellectual property strategy should aim to develop a qualitative patent portfolio for continuous learning. This book addresses questions of ethics, socio-political policies and regulatory aspects of novel Nanomedicine-based products which are currently under development for the diagnosis and treatment of different types of diseases. It is divided in two parts - Part I is composed of the first 3 chapters, which focus on the "fundamentals" of legal aspects, emerging threats, advantages and disadvantages of patenting Nanomedicines, whereas Part II collects 12 chapters discussing different types of Nanomedicine-based products, their potential marketing aspects and patent protection. Whenever applied, each chapter offers a list of patents, based on a specific application in drug delivery and targeting. An outstanding team of 53 authors have contributed to this book, which will be of interest to professionals from the field of patent examiners, academics, researchers and scientists, students and other practitioners.

Direct Nose-to-Brain Drug Delivery provides the reader with precise knowledge about the strategies and approaches for enhanced nose-to-brain drug delivery. It highlights the development of novel nanocarrier-based drug delivery systems for targeted drug delivery to the brain microenvironments with a focus on the technological advances in the development of the novel drug delivery devices for intranasal administration, including special emphasis on brain targeting through nose. This book explores the various quantification parameters to assess the brain targeting efficiency following intranasal administration and includes an overview on the toxicity aspects of the various materials used to develop the direct nose-to-brain drug delivery vehicles and of the regulatory aspects including patents and current clinical status of the potential neurotherapeutics for the effective management of neuro-ailments. Technological advances in new drug delivery systems with diverse applications in pharmaceutical, biomedical, biomaterials, and biotechnological fields are also explained. This book is a crucial source that will assist the veteran scientists, industrial technologists, and clinical research professionals to develop new drug delivery systems and novel drug administration devices for the treatment of neuro-ailments.

Dry eye syndrome is a common disease of tear film and ocular surface developed in numerous aetiologies. Tear film instability and ocular surface disturbances that subsequently influence the tear film are among the primarily causes of this disease, but many other factors are involved in tear film disorders. Although eye surface is easily reached by classical ocular dosage forms, novel drug delivery systems for ocular administration offer advantages in terms of increased residence time on eye surface and/or controlled release of the drug, with enhanced therapeutic effectiveness. This book provides an overview on the potential benefits and limitations in dry eye syndrome management and reported successful formulations.